Almirall presents clinical, real-word data across portfolio at AAD meeting

Almirall (LBTSF) is presenting a broad range of clinical and real-world data across its portfolio at the 2026 American Academy of Dermatology Annual Meeting. The company’s presence includes more than 15 scientific posters, led by 9 lebrikizumab presentations in atopic dermatitis, new analyses on tirbanibulin, two on tildrakizumab from the POSITIVE study, and two sarecycline pooled Phase 3 evaluations in acne. “Our goal is to bring meaningful, evidence-based treatment options to people living with skin diseases. The breadth of data we are sharing at AAD 2026 – from long-term results and real-world evidence for lebrikizumab to clinically relevant AK endpoints with tirbanibulin – reflects our commitment to rigorous science, patient-centred outcomes, and strong collaboration with dermatology partners,” said Dr. Volker Koscielny, Almirall’s Chief Medical Officer.